<DOC>
	<DOCNO>NCT02612116</DOCNO>
	<brief_summary>The purpose study evaluate difference pharmacokinetics pharmacodynamics ticagrelor active metabolite depend strategy drug administration patient unstable angina pectoris .</brief_summary>
	<brief_title>Comparison Administration Strategies Ticagrelor Patients With Unstable Angina Pectoris , Pharmacokinetic / Pharmacodynamic Study</brief_title>
	<detailed_description>On basis current guideline ticagrelor recommend antiplatelet agent acute coronary syndrome , include unstable angina pectoris . According result MOJITO study , perform patient ST-elevation myocardial infarction , effect ticagrelor , measure platelet inhibition , may achieve sooner crushed tablet administer . Thus , may significant difference pharmacokinetics pharmacodynamics ticagrelor pulverize drug give orally sublingually compare currently use oral administration integral tablet . The study design open-label , single-center , randomized trial different strategy administration ticagrelor patient unstable angina pectoris . After enrollment , participant randomize three arm , receive ticagrelor . The drug give : ( 1 ) pulverize tablet administer sublingually , ( 2 ) pulverize tablet administer orally ( 3 ) integral tablet orally . The time require ticagrelor active metabolite AR-C124900XX reach maximum serum concentration measure primary outcome study . Moreover , evaluation parameter include maximum plasma concentration area plasma concentration ticagrelor active metabolite assess secondary outcome . The platelet reactivity measure Multiplate Analyzer .</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Diagnosis unstable angina Male nonpregnant female , age 1880 year old Provision inform consent angiography percutaneous coronary intervention ( PCI ) GRACE score &lt; 140 pt treatment ticlopidine , clopidogrel , prasugrel ticagrelor within 14 day study enrollment hypersensitivity ticagrelor current treatment oral anticoagulant chronic therapy lowmolecularweight heparin active bleed history intracranial hemorrhage recent gastrointestinal bleeding ( within 30 day ) history coagulation disorder platelet count less &lt; 100 x10^3/mcl hemoglobin concentration le 10.0 g/dl history moderate severe hepatic impairment history major surgery severe trauma ( within 3 month ) patient consider investigator risk bradycardic event second third degree atrioventricular block screen eligibility history asthma severe chronic obstructive pulmonary disease patient require dialysis manifest infection inflammatory state Killip class III IV screen eligibility respiratory failure history severe chronic heart failure ( NYHA class III IV ) concomitant therapy strong CYP3A inhibitor ( ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin , nefazadone , ritonavir , saquinavir , nelfinavir , indinavir , atazanavir ) strong CYP3A inducer ( rifampicin , phenytoin , carbamazepine , dexamethasone , phenobarbital ) within 14 day study treatment body weight 50 kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>